Any current/future new fundraising through debt or equity?

The transcript does not mention any current or planned fundraising through debt or equity. The company is focusing on managing existing debt, which stood at Rs. 703 crore as of December 31, 2024. Debt increase recently is attributed mainly to inventory replenishment post the Q1 fire incident, capital expenditure, and GST refund delays. Management highlighted expectations of debt reduction by about Rs. 100 crore in the next 6 months, aided by insurance payouts. Investments are ongoing but appear to be funded through internal accruals and existing debt facilities. No explicit plans were shared r

Any current/future capex/capital investment/strategic investment?

The company has completed major investments in development and production capacities for its Flavours business and expects this phase to be finished for the current size. Further investments in the Flavours business are anticipated in the next 2 years to support continued growth. Recent investments include setting up creative development centers in Europe (UK and Germany) and the USA, focusing on product development teams to serve local and global MNC markets. Capital expenditure of around Rs. 75 crore has been incurred for rebuilding a factory after a fire, expected to be reimbursed substanti

Future growth expectations in sales/revenue/volumes?

Company targets a 12% CAGR growth over the mid to longer term, with recent 9-month performance ahead at nearly 17% YoY growth. Expectation of reaching around Rs. 3,000 crore revenue by FY27, implying approximately 14% CAGR. Major growth contribution expected from volume increases rather than price hikes. Flavours business anticipated to grow at a strong +15% CAGR, faster than the more mature Fragrance business. European business growing healthily at around 12% annually, outpacing the ~2% market average, with potential capacity expansion planned within 1-2 years. New investments in development

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects to maintain a healthy top-line growth of 12% CAGR over the mid to longer term, with FY25 ahead at ~17%. EBITDA margins excluding new geography investments stand at a healthy 17%, with an overall margin guidance of 16%-18% for the upcoming year, despite current subdued margins due to investments. Gross margins are expected to normalize and improve over the next year as pricing actions take effect and raw material supply stabilizes. Investments in Europe, US, and other markets are strategic for long-term growth, expected to drive higher market share, operating leverage,

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the exact current or expected order book or pending orders. However, the company indicates strong demand and growth prospects despite some slowdown in larger Indian domestic accounts. Kedar Vaze highlights a robust 15% year-on-year quarterly growth with no slowdown seen so far. The business is gaining market share, especially in new geographies like Southeast Asia, Middle East, Europe, and the US. New client engagements and product developments are ongoing, supporting a 12%-14% revenue growth guidance. For the global MNC account, business is on track

IN US

Sale is live|00:00:00left today

S H Kelkar & Company LtdQ4 FY26Chemicals & Petrochemicals

S H Kelkar & Company Ltd Q4 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹135P/E: 38.1Market Cap: ₹1.9K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Company targets a 12% CAGR growth over the mid to longer term, with recent 9-month performance ahead at nearly 17% YoY growth.
→Expectation of reaching around Rs. 3,000 crore revenue by FY27, implying approximately 14% CAGR.
→Major growth contribution expected from volume increases rather than price hikes.
→Flavours business anticipated to grow at a strong +15% CAGR, faster than the more mature Fragrance business.
→European business growing healthily at around 12% annually, outpacing the ~2% market average, with potential capacity expansion planned within 1-2 years.
→New investments in development and production capacity across key geographies (Europe, US, SE Asia) to support higher growth from 18-24 months onwards.
→Momentum in India remains robust (~15% YoY growth), with expected growth pickup in early FY26 due to government initiatives boosting consumption.

Margin guidance

Category 3

→The company expects to maintain a healthy top-line growth of 12% CAGR over the mid to longer term, with FY25 ahead at ~17%.
→EBITDA margins excluding new geography investments stand at a healthy 17%, with an overall margin guidance of 16%-18% for the upcoming year, despite current subdued margins due to investments.
→Gross margins are expected to normalize and improve over the next year as pricing actions take effect and raw material supply stabilizes.
→Investments in Europe, US, and other markets are strategic for long-term growth, expected to drive higher market share, operating leverage, and sustained value creation over the next 3 years.
→Flavours segment delivering strong EBIT (~22%) and growth, expected to contribute to margin expansion as growth accelerates.
→Development expenditure (~Rs. 45-48 crore in FY25) will stabilize, with inflation-adjusted increases thereafter, supporting steady earnings growth.
→Overall, earnings and EPS growth are expected to benefit from volume-driven revenue growth, margin expansion, and cost normalization.

3 more insights locked — sign up free to unlock

Fundraise plans

→The transcript does not mention any current or planned fundraising through debt or equity.
→The company is focusing on managing existing debt, which stood at Rs. 703 crore as of December 31, 2024.
→Debt increase recently is attributed mainly to inventory replenishment post the Q1 fire incident, capital expenditure, and GST refund delays.
→Management highlighted expectations of debt reduction by about Rs. 100 crore in the next 6 months, aided by insurance payouts.
→Investments are ongoing but appear to be funded through internal accruals and existing debt facilities.
→No explicit plans were shared regarding fresh debt or equity raising in the near or medium term during the Q3 & 9M FY25 concall.

Order book

→The transcript does not explicitly mention the exact current or expected order book or pending orders.
→However, the company indicates strong demand and growth prospects despite some slowdown in larger Indian domestic accounts.
→Kedar Vaze highlights a robust 15% year-on-year quarterly growth with no slowdown seen so far.
→The business is gaining market share, especially in new geographies like Southeast Asia, Middle East, Europe, and the US.
→New client engagements and product developments are ongoing, supporting a 12%-14% revenue growth guidance.
→For the global MNC account, business is on track to reach $10 million this year, with expected growth of 20%-30% going forward.
→Inventory replenishment and new investments suggest positive order fulfillment outlook, though precise order backlog figures are not disclosed.

Capex plans

Yes

→The company has completed major investments in development and production capacities for its Flavours business and expects this phase to be finished for the current size.
→Further investments in the Flavours business are anticipated in the next 2 years to support continued growth.
→Recent investments include setting up creative development centers in Europe (UK and Germany) and the USA, focusing on product development teams to serve local and global MNC markets.
→Capital expenditure of around Rs. 75 crore has been incurred for rebuilding a factory after a fire, expected to be reimbursed substantially through insurance.
→The company invested approximately Rs. 45-48 crore in FY25 towards development centers and expects this cost to stabilize and grow only by inflation thereafter.
→There are plans to invest in European production capacity within the next 1–2 years to support sales momentum and capacity utilization.
→No plans to expand beyond the current four major markets (Southeast Asia, India, Middle East, Europe, and America) in the near to medium term.

How does S H Kelkar & Company Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1S H Kelkar & Company Ltd

Rev 3Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like S H Kelkar & Company Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio